JP2023506593A5 - - Google Patents

Info

Publication number
JP2023506593A5
JP2023506593A5 JP2022552323A JP2022552323A JP2023506593A5 JP 2023506593 A5 JP2023506593 A5 JP 2023506593A5 JP 2022552323 A JP2022552323 A JP 2022552323A JP 2022552323 A JP2022552323 A JP 2022552323A JP 2023506593 A5 JP2023506593 A5 JP 2023506593A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506593A (ja
JP7566923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021109 external-priority patent/WO2021178814A1/en
Publication of JP2023506593A publication Critical patent/JP2023506593A/ja
Publication of JP2023506593A5 publication Critical patent/JP2023506593A5/ja
Priority to JP2024078761A priority Critical patent/JP2024097985A/ja
Application granted granted Critical
Publication of JP7566923B2 publication Critical patent/JP7566923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552323A 2020-03-06 2021-03-05 抗gitr抗体およびその使用 Active JP7566923B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078761A JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986494P 2020-03-06 2020-03-06
US62/986,494 2020-03-06
PCT/US2021/021109 WO2021178814A1 (en) 2020-03-06 2021-03-05 Anti-gitr antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078761A Division JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2023506593A JP2023506593A (ja) 2023-02-16
JP2023506593A5 true JP2023506593A5 (cg-RX-API-DMAC7.html) 2024-03-05
JP7566923B2 JP7566923B2 (ja) 2024-10-15

Family

ID=75223517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552323A Active JP7566923B2 (ja) 2020-03-06 2021-03-05 抗gitr抗体およびその使用
JP2024078761A Withdrawn JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078761A Withdrawn JP2024097985A (ja) 2020-03-06 2024-05-14 抗gitr抗体およびその使用

Country Status (14)

Country Link
US (2) US11787867B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114859A1 (cg-RX-API-DMAC7.html)
JP (2) JP7566923B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220151172A (cg-RX-API-DMAC7.html)
CN (1) CN115244084A (cg-RX-API-DMAC7.html)
AU (1) AU2021232041A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017156A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168173A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002404A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012467A2 (cg-RX-API-DMAC7.html)
IL (1) IL296043A (cg-RX-API-DMAC7.html)
MX (2) MX2022010910A (cg-RX-API-DMAC7.html)
PH (1) PH12022552295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021178814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545265A (ja) * 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO1999025834A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Th2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
MX2018006072A (es) * 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CA3027121A1 (en) * 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
KR102209364B1 (ko) * 2016-12-09 2021-02-01 리제너론 파아마슈티컬스, 인크. T 세포 수용체를 시퀀싱하기 위한 시스템 및 방법 및 이의 용도
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Similar Documents

Publication Publication Date Title
JP7671377B2 (ja) 抗メソテリン抗体
TWI714864B (zh) 檢查點抑制劑雙特異性抗體
US12384853B2 (en) Anti-HER2/PD1 bispecific antibody
JP2021531764A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
CN106659779B (zh) 双特异性四价抗体及其制造和使用方法
JP2019521098A5 (cg-RX-API-DMAC7.html)
JP2021518103A5 (cg-RX-API-DMAC7.html)
JP2019524693A5 (cg-RX-API-DMAC7.html)
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2019500891A5 (cg-RX-API-DMAC7.html)
RU2017118225A (ru) Антитела к PD-1 и способы их применения
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2019521645A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2020514310A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2023543152A5 (cg-RX-API-DMAC7.html)
JP2019529373A5 (ja) 抗Tim−3抗体
RU2017142008A (ru) Новые полипептиды
CN117946278A (zh) 多特异性抗体及其制备和使用方法
JP2022523066A5 (cg-RX-API-DMAC7.html)
CN114514244A (zh) T细胞活化抗体